Literature DB >> 22518235

Repeated dosing of 23.4% hypertonic saline for refractory intracranial hypertension. A case report.

Alden K Valentino1, Karen M Nau, David A Miller, Ricardo A Hanel, Wd Freeman.   

Abstract

BACKGROUND: Hypertonic saline (HTS) at a concentration of 23.4% is an emerging therapy for intracranial hypertension. Compared to mannitol which can be given as a single bolus or as repeated bolus dosing, little data exists regarding safety or efficacy of repeated dosing of 23.4% HTS. We report the first case of 16 doses of 23.4% HTS over a 5 day period in a patient with refractory intracranial hypertension. CASE REPORT: A 43-year-old woman with Fisher 3 subarachnoid hemorrhage and hydrocephalus requiring an external ventricular drain developed global cerebral edema on computed tomography. Medically refractory intracranial hypertension ensued which required repeated dosing of 23.4% HTS. Reductions in intracranial pressure (ICP) occurred after each dose of 23.4% HTS. No central nervous system complications occurred. Anasarca was the only observed complication, which responded to furosemide diuresis.
CONCLUSION: Repeated dosing of 23.4% HTS was effective in reducing ICP in a case of medically refractory intracranial hypertension without major systemic complications. Prospective studies should address the safety and efficacy of repeat dose 23.4% HTS on serum sodium, intracranial pressure, and complications.

Entities:  

Keywords:  Intracranial hypertension; hypertonic saline; subarachnoid hemorrhage

Year:  2008        PMID: 22518235      PMCID: PMC3317320     

Source DB:  PubMed          Journal:  J Vasc Interv Neurol        ISSN: 1941-5893


  8 in total

1.  Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke.

Authors:  Stefan Schwarz; Dimitrios Georgiadis; Alfred Aschoff; Stefan Schwab
Journal:  Stroke       Date:  2002-01       Impact factor: 7.914

Review 2.  Osmotic therapy: fact and fiction.

Authors:  Michael N Diringer; Allyson R Zazulia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

3.  Reversal of transtentorial herniation with hypertonic saline.

Authors:  M A Koenig; M Bryan; J L Lewin; M A Mirski; R G Geocadin; R D Stevens
Journal:  Neurology       Date:  2008-02-13       Impact factor: 9.910

4.  Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage: comparison between mannitol and hypertonic saline.

Authors:  A I Qureshi; D A Wilson; R J Traystman
Journal:  Neurosurgery       Date:  1999-05       Impact factor: 4.654

Review 5.  Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension.

Authors:  A I Qureshi; J I Suarez
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

Review 6.  The use of hypertonic saline for treating intracranial hypertension after traumatic brain injury.

Authors:  Hayden White; David Cook; Bala Venkatesh
Journal:  Anesth Analg       Date:  2006-06       Impact factor: 5.108

7.  Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: a preliminary study.

Authors:  Marcus L Ware; Venu M Nemani; Michele Meeker; Currie Lee; Diane J Morabito; Geoffrey T Manley
Journal:  Neurosurgery       Date:  2005-10       Impact factor: 4.654

Review 8.  Hypertonic saline: a clinical review.

Authors:  R Tyagi; K Donaldson; C M Loftus; J Jallo
Journal:  Neurosurg Rev       Date:  2007-06-16       Impact factor: 3.042

  8 in total
  2 in total

1.  Safety and efficacy of repeated doses of 14.6 or 23.4 % hypertonic saline for refractory intracranial hypertension.

Authors:  Julie J Lewandowski-Belfer; Alden V Patel; Robert M Darracott; Daniel A Jackson; Jerah D Nordeen; W David Freeman
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

2.  Safety and Tolerability of 23.4% Hypertonic Saline Administered Over 2 to 5 Minutes for the Treatment of Cerebral Herniation and Intracranial Pressure Elevation.

Authors:  Sean K O'Brien; Jennifer L Koehl; Lindsay B Demers; Bryan D Hayes; Megan E Barra
Journal:  Neurocrit Care       Date:  2022-09-28       Impact factor: 3.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.